In addition, Aalen’s Additive Hazards model was applied to examine additive rather than relative hazard effects while allowing time-varying effects. A Cox proportional hazards model was utilized to estimate hazard rate ratios (HR) for MOF, and survival curves were plotted using the Kaplan-Meier estimator. MOF were defined as hip, vertebral, humerus, or forearm fractures. Subjects were propensity-score matched 1:1 based on age, sex, and index date. Subjects treated with metformin in combination with either GLP-1RA or DPP-4i were enrolled from 2007 to 2018. Diagnoses were obtained from discharge diagnosis codes (ICD-10 and ICD-8-system) from the Danish National Patient Registry, and all redeemed drug prescriptions were obtained from the Danish National Prescription Registry (ATC classification system). Methods: We conducted a population-based cohort study using Danish national health registries. We aimed to investigate the risk of major osteoporotic fractures (MOF) for treatment with GLP-1RA compared to dipeptidyl peptidase 4 inhibitors (DPP-4i) as add-on therapies to metformin. There is little evidence for the effects of glucagon-like peptide 1 receptor agonists (GLP-1RA) on fracture risk in T2D. 5Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmarkīackground: Type 2 diabetes mellitus (T2D) is associated with an increased fracture risk.4Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
3Steno Diabetes Center North Jutland, Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.1Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.Zheer Kejlberg Al-Mashhadi 1,2*, Rikke Viggers 3,4, Rasmus Fuglsang-Nielsen 1,2,5, Peter Vestergaard 3,4, Søren Gregersen 1,2 and
0 kommentar(er)
